Home Compare NBIX vs SYK
Stock Comparison · Structural lead, mixed market

Neurocrine Biosciences vs Stryker: Which Stock Looks Stronger in 2026?

Neurocrine Biosciences holds the cleaner structural position, with growth as the main driver and profitability adding further support. Stryker does not offset that deficit through any equally strong structural edge elsewhere. On the market side, Neurocrine Biosciences is in better shape — its trend is intact while Stryker's trend has broken down. That puts structure and market broadly in agreement — Neurocrine Biosciences's lead looks more confirmed than conflicted.

The comparison is based on similar long-term financial trajectories, not sector labels. Both peer scores are relative to the Russell 1000 universe, making them directly comparable.

Updated 2026-07-05

Most of the visible separation comes from growth. The overall score gap is 30 points in favour of Neurocrine Biosciences, Inc..

Trajectory Similarity
0.70
Moderately similar
Peer-set rank: #8
within Neurocrine Biosciences, Inc.'s functional peer set

This comparison is anchored in long-term financial trajectory similarity within the selected peer universe.

This level of similarity points to a meaningful structural match, though not a tight one.

The match is driven mainly by capital structure and revenue stability.

Similarity drivers
capital structurerevenue stability
How to read the score
0.85–1.00 · Very similar0.70–0.84 · Similar0.55–0.69 · Moderately similarbelow 0.55 · Loose match
Peer-Relative Score
NBIX
Neurocrine Biosciences, Inc.
72
Peer-Score
Signal qualitylow
Peer basis: Russell 1000
vs
SYK
Stryker Corporation
42
Peer-Score
Signal qualitylow
Peer basis: Russell 1000

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: NBIX vs SYK Profitability 50 29 Stability 77 62 Valuation 72 52 Growth 98 25 NBIX SYK
Gap Ranking
#1 Growth +73
#2 Profitability +21
#3 Valuation +20
#4 Stability +15
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for NBIX and SYK Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer NBIXSYK Relative valuation Structural strength

Neurocrine Biosciences, Inc. looks stronger on relative valuation, while the broader price setup remains mixed.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Entry today — historical context

Where NBIX and SYK each sit in their own 5-year price and valuation history.

BASED ON 5-YEAR HISTORY NBIX Elevated · below norm 0th 50th 100th 42 pct gap SYK Neutral · below norm 0th 50th 100th 99th 58th
Today SYK sits in the upper-middle of its own 5-year history (58th percentile), while NBIX sits higher in its own history (99th). Within each stock's own 5-year context, SYK is at a historically more favourable entry position than NBIX. This reflects entry timing, not which company is structurally stronger — peer-relative analysis is a separate question addressed above.

Describes historical entry positioning only. Descriptive — not investment advice.

Relative Position vs Comparable Companies
Growth
On growth, Neurocrine Biosciences, Inc. ranks near the top of the group; Stryker Corporation sits in the weaker half.
Profitability
On profitability, Neurocrine Biosciences, Inc. is positioned higher in the group, while Stryker Corporation is closer to the middle.
Growth — Dominant Gap
NBIX
98
SYK
25
Gap+73in favour of NBIX

Growth adds another layer to the lead, with a very wide gap in revenue growth between the two companies.

What else supports the lead

Capital efficiency adds support, with a 6.5-point ROIC advantage.

What this means for the comparison

Growth is the clearest driver, and profitability also supports Neurocrine Biosciences, Inc.'s broader structural position.

Explore full peer positioning in AssetNext

Break down the NBIX vs SYK comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar growth-driven comparisons

Explore how NBIX and SYK each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.